drugset / Trial / NCT05344976
MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, open-label Phase I study to evaluate the safety and efficacy of MSLN STAR-T cell immunotherapy in the treatment of advanced malignant solid tumors.
Timeline
- Start
- 2022-04-14
- Primary completion
- 2024-10-14
- Completion
- 2026-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSLN STAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Subject | MSLN STAR-T cells | Cell therapy | 1e+08 cells/kg | Intravenous |
Indications
No indication recorded.